Effects of intravenous immunoglobulin on muscle weakness and calcium- channel autoantibodies in the Lambert-Eaton myasthenic syndrome

Neurology

Volumn 47, Issue 3, 1996, Pages 678-683

  Bain, P G ^a   Motomura, M ^a   Newsom Davis, J ^a,d   Misbah, S A ^b   Chapel, H M ^b   Lee, M L ^c   Vincent, A ^a   Lang, B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; ALBUMIN; ALPHA GLOBIN; CALCIUM CHANNEL; CHLORPHENIRAMINE; HYDROCORTISONE; IMMUNOGLOBULIN G; INDOMETACIN; IODINE 125; OMEGA CONOTOXIN MVIIC; PLACEBO; PREDNISOLONE;

ADULT; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG THERAPY; EATON LAMBERT SYNDROME; FEMALE; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUSCLE STRENGTH; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0029819742     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.3.678     Document Type: Article

References (28)

1. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
2. Van der Meché FGA, Schmitz PIM, Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-1129.
3. Van Doom PA, Brand A, Strengers PFW, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled crossover study. Neurology 1990;40:209-212.
4. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-116.
5. Lang B, Newsom-Davis J, Wray D, Vincent A, Murray NMF. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981;2:224-226.
6. Lambert EH, Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann NY Acad Sci 1971;183:183-199.
7. Fukunaga H, Engel AG, Osame M, Lambert EH. Paucity and disorganisation of presynaptic membrane active zones in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1982;5: 686-697.
8. Lang B, Newsom-Davis J, Prior C, Wray D. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. J Physiol (Lond) 1983;344:335-345.
9. Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci USA 1983;80:7636-7640.
10. Lang B, Newsom-Davis J, Peers C, Prior C, Wray DW. The effect of myasthenic syndrome antibody on presynaptic calcium-channels in the mouse. J Physiol (Lond) 1987;390:257-270.
11. Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995;58:85-87.
12. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467-1474.
13. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988;111:577-596.
14. Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990;40:1552-1556.
15. 2+ flux in a human small cell carcinoma line. Nature 1985:317:737-739.
16. Newsom-Davis J, Murray NMF. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984;34:480-485.
17. Bird SJ. Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology 1992;42:1422-1423.
18. Tabbaa MA, Leshner RT, Campbell WW. Malignant thymoma with dysautonomia and disordered neuromuscular transmission. Arch Neurol 1986;43:955-957.
19. Bain P, Elrington G, Goodger E, et al. A randomised double blind controlled study of intravenous immunoglobulin in the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1994;57:1287.
20. Wiles CM, Karni Y, Nicklin J. Laboratory testing of muscle function in the management of neuromuscular disease. J Neurol Neurosurg Psychiatry 1990;53:384-387.
21. Nathadwarawala KM, Nicklin J, Wiles CM. A timed test of swallowing capacity for neurological patients. J Neurol Neurosurg Psychiatry 1992;55:822-825.
22. Wiles CM, Karni Y. The measurement of muscle strength in patients with peripheral neuromuscular disorders. J Neurol Neurosurg Psychiatry 1983;46:1006-1013.
23. Palace J, Wiles CM, Newsom-Davis J. 3,4-diaminopyridine in the treatment of congenital (hereditary) myasthenia. J Neurol Neurosurg Psychiatry 1991;54:1069-1072.
24. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. Philadelphia: Lea & Febiger 1980;288-291.
25. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993;9:254-262.
26. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-262.
27. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-1611.
28. Liblau R, Gajdos Ph, Bustarret FA, El Habib R, Bach JF, Morel E. Intravenous γ-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies. J Clin Immunol 1991;11:128-131.